HealthEquity, Inc
HQY
$87.84
-0.94%
HealthEquity, Inc. operates in the healthcare information services sector, specializing in administering and managing consumer-directed health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), and other tax-advantaged healthcare savings and spending solutions for employers and individuals. The company is a leading provider in the HSA and consumer-directed benefits space, acting as a critical intermediary that facilitates healthcare payments, provides personalized benefit information, and offers investment advisory services for account holders. The current investor narrative is shaped by the company's recovery from a significant price decline earlier in the year, with attention focused on its ability to return to growth, improve profitability, and navigate a competitive landscape as a consolidator in the fragmented HSA market.…
HQY
HealthEquity, Inc
$87.84
HQY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HealthEquity, Inc's 12-month outlook, with a consensus price target around $114.19 and implied upside of +30.0% versus the current price.
Average Target
$114.19
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$70 - $114
Analyst target range
Analyst coverage for HQY is limited, with only 4 analysts providing estimates, which is low for a company of its market cap and suggests it may be underfollowed by the broader institutional research community, potentially leading to higher volatility and less efficient price discovery. The available data shows a consensus EPS estimate of $6.16 for the upcoming period, with a relatively narrow range from $5.99 to $6.33, indicating a high degree of confidence in the earnings forecast among the few covering analysts. The recent institutional rating actions, including a downgrade to Sell from Goldman Sachs in January 2026, contrast with a series of reiterated Buy/Overweight ratings from other firms, signaling a divergence of opinion on the stock's prospects and contributing to the current uncertainty in its price action.
Bulls vs Bears: HQY Investment Factors
The evidence presents a classic value versus growth stagnation dilemma. The bear case is supported by the stark technical reality: a stock in a deep, long-term downtrend that has severely underperformed the market, coupled with only modest revenue growth. However, the bull case is grounded in compelling fundamentals: exceptional profitability, strong cash flow, a healthy balance sheet, and a forward valuation that prices in a significant earnings recovery. Currently, the bearish technical and growth momentum evidence slightly outweighs the bullish fundamental value proposition, as the stock has yet to prove it can break its downtrend. The single most important tension is whether the company can deliver on the earnings growth implied by its low forward P/E (15.7x) to justify a re-rating, or if the current modest revenue trajectory will lead to further multiple compression from its still-high trailing P/E (34.3x).
Bullish
- Strong Profitability & Operating Leverage: The company exhibits robust profitability with a trailing net margin of 16.38% and a high gross margin of 69.5%. This demonstrates the scalability of its platform business model, as evidenced by an operating margin of 24.6% in the latest quarter.
- Compelling Forward Valuation: The stock trades at a forward P/E of 15.7x, a significant discount to its trailing P/E of 34.3x, implying the market expects earnings to more than double. This forward multiple is reasonable for a profitable company with strong cash flow generation.
- Exceptional Financial Health & Cash Flow: HealthEquity has a fortress balance sheet with a current ratio of 3.27 and low debt-to-equity of 0.48. It generated $439.1M in TTM free cash flow, providing ample liquidity for shareholder returns and strategic investments without financial stress.
- Recent Positive Momentum: The stock has shown signs of a tentative recovery, gaining 9.79% over the past three months and 4.11% over the past month. This technical improvement from the 52-week low of $72.76 suggests potential stabilization after a severe downtrend.
Bearish
- Severe Underperformance & Downtrend: The stock is down 23.91% over the past year, massively underperforming the S&P 500 by over 50 percentage points. It remains 26% below its 52-week high, indicating a sustained primary downtrend that has not been decisively broken.
- Modest & Potentially Decelerating Growth: Recent quarterly revenue growth of 7.3% YoY is modest for a growth stock. Furthermore, Q4 revenue of $334.6M declined sequentially from Q3's $325.8M, raising concerns about near-term growth momentum and top-line acceleration.
- High Trailing P/E & Valuation Compression Risk: The trailing P/E of 34.3x is elevated for a company with single-digit revenue growth. If the anticipated earnings acceleration fails to materialize, the stock faces significant valuation compression risk, as its price remains disconnected from current earnings.
- Divergent Analyst Sentiment & Low Coverage: With only 4 analysts covering the stock, it is underfollowed, which can lead to inefficient price discovery. Sentiment is mixed, highlighted by a Goldman Sachs downgrade to Sell in January 2026, contrasting with other Buy ratings, creating uncertainty.
HQY Technical Analysis
The stock is in a sustained downtrend, evidenced by a significant 1-year price change of -23.91%, and is currently trading near the middle of its 52-week range, approximately 33% above its 52-week low of $72.76 and 26% below its 52-week high of $116.65. This positioning suggests the stock is consolidating after a substantial decline, presenting a potential value opportunity but also indicating a lack of decisive bullish momentum. Recent momentum shows signs of a tentative recovery, with the stock up 4.11% over the past month and 9.79% over the past three months, which contrasts sharply with the longer-term downtrend and could signal a potential reversal or a bear market rally. The stock's beta of 0.187 indicates it has been significantly less volatile than the broader market (SPY), which was up 27.04% over the past year, suggesting the stock has exhibited defensive characteristics and has massively underperformed the market by over 50 percentage points on a relative strength basis. Key technical support is at the 52-week low of $72.76, while resistance is at the 52-week high of $116.65; a sustained break above the recent trading range near $90 could signal the start of a more durable recovery, while a breakdown below $73 would likely confirm the continuation of the primary downtrend.
Beta
0.21
0.21x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$73-$117
Price range past year
Annual Return
-21.3%
Cumulative gain past year
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | +0.2% |
| 3m | +11.9% | +9.2% |
| 6m | -8.2% | +7.5% |
| 1y | -21.3% | +23.4% |
| ytd | -3.5% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HQY Fundamental Analysis
Revenue growth has been modest but positive, with the most recent quarterly revenue of $334.6 million representing a 7.3% year-over-year increase; however, sequential quarterly revenue has fluctuated, showing a slight decline from the $325.8 million reported in the prior quarter, indicating potential near-term growth deceleration. The company is profitable, reporting net income of $49.74 million for the latest quarter and a trailing twelve-month net margin of 16.38%, with gross margins exceptionally strong at 69.5% and operating margins at 24.6%, reflecting a highly scalable platform business model with significant operating leverage. Financial health is robust, as evidenced by a strong current ratio of 3.27, a manageable debt-to-equity ratio of 0.48, and substantial free cash flow generation of $439.1 million over the trailing twelve months, providing ample liquidity to fund operations and shareholder returns without reliance on external financing, as demonstrated by consistent stock repurchase activity.
Quarterly Revenue
$334586000.0B
2026-01
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.92%
Latest Quarter
Free Cash Flow
$439068000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HQY Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E stands at 34.3x, while the forward P/E is significantly lower at 15.7x, indicating the market is pricing in a substantial acceleration in earnings growth over the next year, likely driven by margin expansion and continued operational efficiency. Compared to its own historical range, the current trailing P/E of 34.3x is below the elevated levels seen in recent quarters (e.g., 90.8x in Q4 2025 and 325.8x in Q3 2024) but remains above the lows near 35x seen in mid-2025, suggesting the valuation has normalized from extreme levels but is not at a deep historical discount. The forward P/E of 15.7x appears more reasonable, reflecting expectations for earnings to more than double from the TTM EPS of $0.03, aligning with analyst estimates for EPS of approximately $6.16.
PE
34.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -6166x~326x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation compression, as the stock trades at a trailing P/E of 34.3x against modest 7.3% YoY revenue growth, creating a high bar for earnings performance. While the balance sheet is strong (D/E 0.48), the company faces execution risk in accelerating growth to meet the forward P/E's implied doubling of earnings. Revenue growth has shown signs of deceleration on a sequential basis, and any failure to meet the high analyst EPS estimate of $6.16 would likely trigger a significant downward re-rating given the current premium valuation on a trailing basis.
Market & Competitive Risks: The stock's extremely low beta of 0.187 indicates it has been treated as a defensive holding, causing it to massively underperform the broader market (relative strength -50.95% over one year). This creates a sector rotation risk; if growth stocks fall out of favor, HQY may not benefit from rallies but could still decline. Competitive risks in the fragmented HSA administration market could pressure pricing and margins. Furthermore, the stock trades at a Price/Sales ratio of 5.6x and an EV/EBITDA of 25.0x, which are not cheap relative to many value-oriented sectors, leaving it vulnerable to multiple contraction if interest rates remain elevated.
Worst-Case Scenario: The worst-case scenario involves a failure to achieve the anticipated earnings recovery, combined with a broader market downturn that hits all equities. This could trigger a cascade of analyst downgrades following the Goldman Sachs Sell rating, leading to a re-test and break below the 52-week low of $72.76. Given the stock's history of high P/E multiples (previously above 300x) and its current -23.9% one-year decline, a realistic downside scenario could see the stock fall to the $65-$70 range, representing a further 20-25% decline from the current price of ~$86. This would align with a forward P/E compression to the low teens, reflecting lost confidence in the growth narrative.